

The TMC Accelerator for Cancer Therapeutics (ACT) in Collaboration with the National Cancer Institute's Small Business Innovation Research Development Center Presents:

Small Business Funding Opportunities from the National Cancer Institute

Tuesday, August 11th 1:00 - 2:30 pm CST Register for the Virtual Session Here
Registration closes July 31st.

The National Cancer Institute's Small Business Innovation Research (NCI SBIR) Development Center provides funding, networking, and mentoring assistance to small businesses with early-stage innovative cancer technology projects. NCI SBIR Team Leader Greg Evans and Program Directors Christie Canaria and Nancy Kamei will present funding opportunities and commercialization resources for entrepreneurs and small businesses.

This presentation is appropriate for both established and emerging entrepreneurs in small businesses or academia interested in moving life science technologies to patients and/or marketplace. The presentation will cover the following topics:

- Overview of SBIR/STTR eligibility requirements
- New and existing funding opportunities from NIH and NCI
- Resources such as the I-Corps™ at NIH Program and Applicant Assistance Program
- Initiatives to help NCI SBIR-funded companies to connect with investors, venture capitalists, strategic partners, and business leaders from the biotech and pharmaceutical industries
- Practical strategies on how to successfully submit competitive research proposals

One-on-One Meeting Opportunities with NCI

NCI SBIR staff are available to meet with select researchers to discuss potential projects one-on-one following the virtual event. Interested parties should send a one-page executive summary/specific aims page to Ashley Francis, TMC ACT Program Manager, at afrancis@tmc.edu by July 31st.







The TMC ACT program is a CPRIT backed accelerator launched in collaboration with the Gulf Coast Consortium (GCC) and the University of Texas Medical Branch (UTMB). This program provides life science entrepreneurs an accelerated drug development timeline by bringing together cancer researchers, oncologists, executive mentorship, drug development experts, and investors. Applications for the program will open in August 11, 2020.